Cantargia Reports 70% Response Rate With Nadunolimab Combination in Early MDS Trial

PUBT · 19h ago
Cantargia Reports 70% Response Rate With Nadunolimab Combination in Early MDS Trial
  • Cantargia published early results from a Phase 1b/2a trial of nadunolimab in two difficult-to-treat blood cancers.
  • Nadunolimab combinations produced remissions in higher-risk myelodysplastic syndromes and adverse-risk relapsed or refractory acute myeloid leukemia.
  • Only one severe adverse event, an infusion-related reaction, was considered likely related to nadunolimab.
  • The Phase 2a expansion is enrolling patients, with total trial enrollment expected to reach approximately 40.
  • Updated longer-term results will be presented orally at the American Society of Hematology annual meeting in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.